OUR MISSION

Architecting the Future of TechBio

At NelGaard Capital, we don't just invest in companies; we architect them. We believe the next century of innovation sits at the intersection of Synthetic Biology, AI-driven Velocity, and Scalable Infrastructure.

Our mission is to bridge the gap between "breakthrough science" and "institutional-grade ventures." We provide the foundational architecture—seed capital, intellectual property strategy, and operational leadership—to help visionary founders transform high-potential platforms into the industry-standard companies of tomorrow.

ABOUT NELGAARD

The Founding Engine

NelGaard Capital is a Pre-Seed and Seed-stage Venture Architect firm. We specialize in identifying undervalued biological assets and platform technologies that solve the massive infrastructure constraints of the modern era. Our philosophy is built on AI-driven Velocity: leveraging computational modeling and programmable biology to collapse the traditional 10-year development cycle into high-velocity commercial pivots.

The Venture Architect Model Our approach is hands-on and infrastructure-centric. We act as a "Founding Engine" for our portfolio companies:

  • IP Fortress Building: We lead the assembly and protection of core intellectual property.
  • Strategic Spin-outs: We specialize in identifying and acquiring latent assets to pivot them toward public market readiness.
  • Industrial Partnerships: We forge transformative alliances to ensure our platforms reach commercial scale rapidly.
  • Operational Leadership: We recruit elite leadership and provide the strategic governance required to navigate the path from Seed to IPO or M&A.

PORTFOLIO HIGHLIGHTS

Infrastructure for the Next Century

NelGaard is the architect behind a new generation of "Frontier TechBio" platforms:

  • Mimulus Corp

    Solving the global data crisis by industrializing Molecular Archive Technology™. By combining CMOS technology with synthetic biology, Mimulus is creating the world's first carbon-neutral, century-scale archival storage system.

  • Cellari Therapeutics

    Developing mRNA-based neuromodulation. By targeting the SNARE pathway with programmable therapeutics, Cellari is building a future of precision medicine for neuromuscular conditions.

  • Racer Biosciences

    Revolutionizing molecular biology workflows with F1-X™ technology, providing the essential tools that accelerate the global synthetic biology supply chain.

  • DIENEI Co

    DIENEI reimagines merchandise for the entertainment industry and beyond, transforming DNA into a medium for expression and memory.

  • Coming Soon

    Stay tuned as we add to our growing portfolio.